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At the present, the immunosuppression applied after kidney transplan­
tation has reached its relative climax. This can be explained by the fact that 
the application of these preparations is to a certain extend constricted by 
their toxicity and possible complications provoked by them leading to fatal 
end. At the moment there is a serious necessity of further development of the 
methods and ways of applications of immunosuppression. The required tol-
lerance towards the transplanted organ by using only immunological methods 
is undoubtfully a perspective direction, but it is a future achievement. At 
the present there is certain activity in studying and approbation of new prepa­
rations. Thus, for example, only in USSR are studied many new medicines 
such as: batriden, megosin, phentirin, dactinomycin, preparations from the 
group of antioxidants, etc. Again the application of A L G and other biologi­
cal products is suggested and tested. 
During the period between 1975 and 1981 in the Institute of Transplan­
tation and Artificial Organs, Moscow, USSR, were studied the Soviet antilym-
phocyte globulins (ALG) : Belorussian "Antilymphocyte immunoglobulin". 
Leningrad "Antilympholin" and Tashkent A L G (only with 49 patients), also 
the foreignmade biological preparation from blood "Retroplacental gamma­
globulin" (RPGG) with 29 patients. 
The first applications of these preparations until 1978 proved their ef­
ficiency; however, they shew certain side effects — thrombopenia and increa­
sed pyrogeneity. The latter disadvantages were overgone and A L G are pro­
duced in larger quantities now. The present work shows the results of appli­
cation of A L G to patients with transplanted kidneys, operated in 1981 and 
treated with A L G in a complete course. 
"Antilymphocyte immunoglobulin" is produced in the Belorussian Scien­
tific Institute of Epidemiology and Microbiology. The preparation itself is 
an immunoglobulin towards human lymphocytes, consisting of gamma-glo­
bulin and Т-fractions of the globulin; it is produced by using horse serum se­
dimentation after immunization with human tonsillar and thymus lympho­
cytes and possessing antibodies against human lymphocytes. The prepara­
tion was applied to 14 patients; the correlative analysis was done together 
with the group of patients treated with A L G (11 patients) and the control 
one without A L G (11 patients). 
The preparation was applied intravenously in mean doses (15—20 mg/kg 
protein in 24 hours) in dilutions up to 200—300 ml saline solution every day 
for the first 30 days, followed by twice a week for the next 2—3 months. In 
the course of rejection crisis with 2 patients the dose was doubled (30—32 mg/kg 
protein in 24 hours), thus having satisfactory results the treatment of rejec­
tions. The intradermal test for A L G sensitiveness was positive in 3 of the 
patients and this was the reason the latter were not treated with that prepa-
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ration. Complications after A L G treatment were not detected. Side effects 
in the course of application were febrile conditions with temperature up to 
37.5—38.0° С (4 patients) at the end of application of the preparation; it can 
be explained by the pyrogeneity of the saline solution or by the rapid A L G -
application. 
In clinical conditions was investigated the lymphopenical effect — 
lymphopenia was preserved for a period up to 18 hours. Lymphopenia was a 
result of an expressed rod-like nuclear neutrophilia. A L G decreased the amount 
of T-lymphocytes 2.5—6 times in laboratory conditions and 1.6—3 times — 
that of B-lymphocytes. A delayed rossette-formation under the influence of 
A L G was registered in dilutions even up to 1:2112 which proved the consi­
derable biological activity of the preparation. 
Analysis of the results of transplanted kidneys shows the following: In 
the group of patients treated by A L G at the end of the 6-th month of graft-
functionating 91 % of all patients were alive and in normal status. In the group 
of patients to whom A L G was not applied the functionating kidneys for the 
same period were 73% and 81% of the patients were alive in relatively normal 
status. The difference between both groups, concerning the graft-functionat­
ing, was with 18% for the first group, showing undoubtfully better results 
of the operative issue. The number of rejection crises of each patients with 
applied A L G in the first month after transplantation was 2 times less than 
that of each patient from the group without A L G . The index of rejection fre­
quency for the first group was 0.4 and for the second one— 0.9. Three months 
later these indexes were 0.6, respectively 1.1. At the end of the 6-th month 
they were 0.6 and 1.4. In this way "Antilymphocyte immunoglobulin" (Belo-
russian production) improves the parameters showing graft-functionating 
with 18%, mainly due to the less number of rejection crises in the early post­
operative periods. 
Retroplacental gamma-globulin (RPGG) was applied to 29 patients. The 
preparation was produced by the Austrian Company "IMMUNO". It is pro­
duced from retroplacental blood taken from the women just after labour. It 
can be suggested that in the protein preparation derived from this blood cer­
tain suppressive substances can be found with block activity towards eff^c-
tory mechanisms of immunity, but the mechanism of the action of the prepa­
ration itself is not clear at the moment. The scheme of application is almost 
similar to that of A L G intravenously. Based on the data of Rogozin Kidney 
Center (USA) R P G G improves the results of the graft-functionating for a pe­
riod of 2 years with 15% (first transplantation) or 30% (second transplanta­
tion). 
Our experience of RPGG-application shows that the preparation fim­
proves the results of graft-functionating in the most early posttransplantation 
periods (in the first 3 months) with 22% due to less rejection crises. The index 
of rejection frequency of each patient from the group with R P G G is 0.6 and 
from the group without R P G G — 1.1. Later results. 1 and 1.5 year later, 
were different from the control group with 3% concerning better results of 
graft-functionating and 2 years after operation — with 8% 
As a conclusion we presume that the application of biological preparations 
in the complex immunosuppression improves the results of the graft-functio­
nating, the early postoperative periods are with less complications, the number 
of rejection crises is decreased, the registered crises are with narrow symptoms 
and easier treated, in the late periods the number of crises is also less and the 
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final results of functionating are quite satisfactory. A L G and R P G G influence 
positively the transplantation immunity and their application is strongly 
recommended to patients with "immunological factors of risk". 
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Авторы исследовали советские антилимфоцитарные глобулины — Белорусский 
«Антилимфоцитарный иммуноглобулин», Ленинградский «Антилимфолин» и Ташкент­
ский АЛГ (всего у 49 больных) и зарубежный биологический препарат крови «Ретропла-
центарый гамма-глобулин» (РПГГ) у 29 больных. Анализированы результаты трансплан­
тации почки у больных, получавших и неполучавших АЛГ. Применение этих препара­
тов в комплексной иммуносупрессии улучшает результаты трансплантации почки, более 
благоприятно проходит ранный послеоперационный период, уменьшается число кризов 
отторжения. 
